Head and Neck Cancer News and Research RSS Feed - Head and Neck Cancer News and Research

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine's NCI-designated Albert Einstein Cancer Center have found. [More]
Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on Lamellasome™ technology, is pleased to announce the publication of a paper in the Supportive Care in Cancer Journal. [More]
Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck cancer. [More]
Immunotherapy could be the future of cancer treatments

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." [More]
Experts create new guidelines to improve treatments for cancer patients

Experts create new guidelines to improve treatments for cancer patients

A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. [More]
New study finds familial risk and heritability of cancer among twins

New study finds familial risk and heritability of cancer among twins

A large new study of twins has found that having a twin sibling diagnosed with cancer poses an excess risk for the other twin to develop any form of cancer. Among the 23 different types of cancer studied, an excess familial risk was seen for almost all of the cancers, including common cancers such as breast and prostate cancer, but also more rare cancers such as testicular cancer, head and neck cancer, melanoma, ovarian and stomach cancer. [More]
E-cigarettes damage cells in ways that could lead to cancer

E-cigarettes damage cells in ways that could lead to cancer

Adding to growing evidence on the possible health risks of electronic cigarettes, a lab team at the Veterans Affairs San Diego Healthcare System tested two products and found they damaged cells in ways that could lead to cancer. The damage occurred even with nicotine-free versions of the products. [More]
FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. [More]
SciClone plans to pursue development of SGX942 in the Greater China market

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis. [More]
Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen Pharmaceuticals, Inc. announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer. [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer. [More]
Discovery could pave way for targeted therapies to treat penile cancer

Discovery could pave way for targeted therapies to treat penile cancer

Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments. [More]
Improved Survival In HPV-Positive Oropharyngeal Cancer Patients Confirmed

Improved Survival In HPV-Positive Oropharyngeal Cancer Patients Confirmed

A large population-based study has confirmed the association between the presence of human papillomavirus DNA in oropharyngeal squamous cell cancer and improved patient survival. [More]
New tool could help identify patients most likely to benefit from chemoprevention

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. [More]
WSU scientist wins federal grant to explore metabolism pathways, tobacco carcinogens

WSU scientist wins federal grant to explore metabolism pathways, tobacco carcinogens

A Washington State University researcher has received a $2.6 million federal grant to study the body's ability to keep tobacco smoke components from causing cancer. [More]
Radical surgery associated with overall survival benefits among patients with advanced throat cancer

Radical surgery associated with overall survival benefits among patients with advanced throat cancer

Patients with cancers of the mid- and lower throat may have higher survival rates if their initial treatment includes surgery, according to new research presented to the 2015 European Cancer Congress today (Saturday). [More]
Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Johns Hopkins scientists discover earliest premalignant genetic changes that mark potential onset of lung cancer

Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease. [More]
PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors. [More]
Researchers identify new way to predict effectiveness of chemotherapy in head and neck cancer patients

Researchers identify new way to predict effectiveness of chemotherapy in head and neck cancer patients

Manchester researchers have identified a potential new way to predict which patients with head and neck cancer may benefit most from chemotherapy. [More]
Advertisement